Blue Horizon International does not offer or provide medical treatment or see patients within the United States. Our cellular and exosome products are investigational and are not approved by the U.S. FDA. This website is for informational and educational purposes only and is not medical advice.

Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

Close Appointment form

Dr. Brian Mehling presents in Monaco

  • Home
  • Dr. Brian Mehling presents in Monaco

News

Dr. Brian Mehling presents in Monaco

Nov 14, 2019 by BHI

Research notice: This page summarizes investigational research for scientific and educational purposes only. The cell-based products discussed are investigational, are not approved by the U.S. FDA, and have not been shown to be safe or effective for any disease or condition. Results from early-stage or retrospective studies are preliminary and are not claims about any BHI product. This is not medical advice.

Brian Mehling, MD, and Michael Kelly, MD had a successful presentation at the Princess Grace Hospital Monaco in Monte Carlo, France. 

Dr. Brian Mehling’s presentation was focused on BHI Therapeutic Sciences (BHITS) stem cell research studies.

It included BHITS stem cell therapy methods, results of Institutional Review Board approved stem cell research studies, resent advances in BHITS stem cell research (Presentation at the American Academy of Orthopedic Surgeons Annual Meeting, New Orleans, Louisiana, 2018 and Presentation at the conference Adult Stem Cells and Regenerative Medicine. The New York Academy of Sciences, NY, 2019) and information on FDA endorsed Investigational New Drug (IND) application entitled Evaluation of the Safety and Efficacy of HPC, Cord Blood in Subjects With Acute Ischemic Stroke.

Dr. Michael Kelly’s presentation was specifically focused on BHITS follow-on IND application entitled “Evaluation of the Safety and Efficacy of Hematopoietic Progenitor Cells, Cord Blood in Subjects with Knee Osteoarthritis Associated Pain”.

It described the study objectives, inclusion and exclusion criteria, safety and efficacy endpoints.

1

  • Share This

About the author

Related Posts

About Blue Horizon International

Blue Horizon International is a healthcare-management and research organization focused on advancing scientific research and education in regenerative medicine. We collaborate with academic and clinical partners, including affiliations with university research institutions, and our affiliates operate in accordance with the applicable regulatory requirements of the jurisdictions in which they are licensed. Our cellular and exosome products are investigational and are not approved by the U.S. FDA.

The statements on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). Our cellular and exosome products are investigational, are not FDA-approved, and are not intended to diagnose, treat, cure, or prevent any disease. The information provided here is for educational purposes only and is not medical advice.

Recent News
Address
Blue Horizon International, LLC 214 State Street, Suite 101 Hackensack, NJ 07601 | USA
Get in touch with us

© 2026 Blue Horizon International, LLC. All rights reserved. This website is only intended for consumers outside the United States.